City Therapeutics Builds RNAi Pipeline with $99.5M Series B

Why It Matters

The capital injection fast‑tracks the development of non‑hepatic RNAi therapeutics, a segment poised for significant clinical and commercial growth. Success could reshape treatment options for clotting disorders and other hard‑to‑target diseases.

Key Takeaways

• City Therapeutics raised $99.5M Series B funding.
• Lead candidate CITY-FXI targets Factor XI for clot prevention.
• Platform uses trigger molecules to reach non‑liver tissues.
• Biogen partnership could be worth up to $1B for CNS therapy.
• Backers include Regeneron Ventures, ARCH Venture Partners, and Sofinnova.

Pulse Analysis

5 million Series B round underscores the growing investor appetite for next‑generation RNA interference platforms. Launched in late 2024 with a $135 million Series A, the Cambridge‑based biotech is led by former Alnylam CEO John Maraganore, whose reputation adds credibility to the raise. The new capital will fund the advancement of its lead candidate CITY‑FXI, a Factor XI inhibitor aimed at preventing thromboembolic events without heightened bleeding risk, and push other pre‑clinical programs toward clinical entry.

Backers such as Regeneron Ventures and ARCH Venture Partners signal confidence in the company’s strategic vision. The core of City’s differentiation lies in its trigger‑molecule platform, which pairs siRNA payloads with targeting ligands capable of delivering therapeutics to a broad array of tissues beyond the liver. This approach could unlock RNAi treatments for diseases such as Stargardt retinal degeneration, central nervous system disorders, and clotting abnormalities—areas where conventional RNAi has struggled. The May 2025 research partnership with Biogen, potentially worth up to $1 billion, validates the platform’s promise and provides a runway for a CNS‑focused candidate that could reshape the market.

From a market perspective, the infusion positions City Therapeutics to compete with established RNAi players like Alnylam and Dicerna while carving a niche in non‑hepatic indications. Successful Phase 1 data for CITY‑FXI would not only de‑risk the program but also attract additional strategic alliances or acquisition interest. With a strong investor consortium and a leadership team experienced in scaling biotech ventures, City is poised to accelerate its pipeline, potentially delivering value to shareholders and expanding the therapeutic reach of RNAi technology.